Estradiol 17β and Its Metabolites Stimulate Cell Proliferation and Antagonize Ascorbic Acid-Suppressed Cell Proliferation in Human Ovarian Cancer Cells. (January 2014)

• Record Type: Journal Article
• Authors: Li, Hui-Hui; Zhao, Ying-Jie; Li, Yan; Dai, Cai-Feng; Jobe, Sheikh O.; Yang, Xing-Sheng; Li, Xing-Fu; Patankar, Manish S.; Magness, Ronald R.; Zheng, Jing
• Is Part Of: Reproductive sciences. Volume 21:Number 1(2014:Jan.)
• Page Start: 102
• Page End: 111
• Publication Date: 2014-01
• Subjects: E2β -- E2β metabolites -- ascorbic acid -- ovarian cancer cells -- growth; Reproductive health -- Periodicals; Reproduction -- Periodicals; 612.6
• DOI: 10.1177/1933719113492211
• Languages: English
• ISSNs: 1933-7191

Abstract

Estradiol 17β (E2 β) and ascorbic acid (AA) have been implicated in cancer progression. However, little is known about the actions of biologically active metabolites of E2 β, 2-hydroxyestradiol (2OHE2 ), 4-hydroxyestradiol (4OHE2 ), 2-methoxyestradiol (2ME2 ), and 4-methoxyestradiol (4ME2 ) synthesized sequentially by cytochrome P450, family 1, subfamily A (CYP1A1) and B (CYP1B1), polypeptide 1, and catechol-O-methyltransferase (COMT) on ovarian cancer. Herein, we examined the expression of CYP1A1, CYP1B1, COMT, and estrogen receptor α (ERα) and β (ERβ) in human ovarian surface epithelial (IOSE-385) and cancer cell lines (OVCAR-3, SKOV-3, and OVCA-432). We also investigated the roles of E2 β, 2OHE2, 4OHE2, 2ME2, and 4ME2 in cell proliferation, and their interactive effects with AA on ovarian cells. We found the expression of CYP1A1, CYP1B1, COMT, ERα, and ERβ in most cell lines tested. Treating cells with physiological concentrations of E2 β and its metabolites promoted (13%-42% of the control) IOSE-385 and OVCAR-3 proliferation. The ER blockade inhibited IOSE-385 (∼76%) and OVCAR-3 (∼87%) proliferative response to E2 β but not to its metabolites. The ERα blockade inhibited (∼85%) E2 β-stimulated OVCAR-3 proliferation, whereas ERβ blockade attenuated (∼83%) E2 β-stimulated IOSE-385 proliferation. The AA at ≥250 μmol/L completely inhibited serum-stimulated cell proliferation in all cell lines tested; however, such inhibition in IOSE-385, OVCAR-3, and OVCA-432 was partially (∼10%-20%) countered by E2 β and its metabolites. Thus, our findings indicate that E2 β and its metabolites promote cell proliferation and antagonize the AA-suppressed cell proliferation in a subset of ovarian cancer cells, suggesting that blocking the actions of E2 β and its metabolites may enhance AA's antiovarian cancer activity.